Steve Butts, Arrivo BioVentures CEO
Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset
Arrivo BioVentures has closed an oversubscribed $45.25 million Series B fundraise with an eye to progress its pipeline through the next stage of trials, including a major depressive disorder (MDD) treatment ready for Phase IIb/III investigation.
The new round brings Morrisville, NC-based Arrivo’s total funds raised to date to $100 million. The Series B comes seven and a half years after Arrivo completed its Series A raise of $49 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
